Bio-Rad Buys GnuBio; Will Focus on NGS-based Dx for Oncology, HLA, Infectious Disease | GenomeWeb

Bio-Rad Laboratories said last week that it acquired next-generation sequencing technology firm GnuBio for an undisclosed price with the goal of commercializing a clinical NGS system.

GnuBio will remain based in Cambridge, Mass., where it is developing a droplet-based next-gen sequencing system that uses "picoinjector" technology developed in Co-founder David Weitz's physics laboratory at Harvard University.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.